Survival for invasive mole and choriocarcinoma

Survival for invasive mole and choriocarcinoma is very high. Nearly all women are cured.

The statistics here are intended as a general guide and can't tell you what is likely to happen in your individual case.

Your doctor can give you more information about your own outlook (prognosis).

You can also talk about this with the Cancer Research UK nurses on freephone 0808 800 4040, from 9am to 5pm, Monday to Friday.

Survival by risk group

Chemotherapy works very well for most women with invasive mole or choriocarcinoma. Those who need chemotherapy are divided into 3 different risk groups - low risk, high risk and ultra high risk disease. 

There are no UK wide statistics for invasive mole and choriocarcinoma.

Results are available from research undertaken at the specialist UK centres that treat these conditions. In this research, women were followed up for between 1 and 16 years after their diagnosis. The number of people included is quite low, particularly for the ultra high risk group.

Low risk disease

All women (100%) with low risk disease are successfully treated.

High risk disease

All those (100%) with high risk disease are successfully treated.

Ultra high risk disease

Around three quarters (75%) of those with ultra high risk disease are successfully treated.

  • Treatment outcomes for 618 women with gestational trophoblastic tumours following a molar pregnancy at the Charing Cross Hospital, 2000-2009.
    A Sita-Lumsden and others
    British Journal of Cancer, 2012. Volume 107. Pages 1810-1814.

  • Gestational Trophoblastic Disease (5th Edition)
    International Society for the Study of Trophoblastic Diseases, 2022

  • Demographics, natural history and treatment outcomes of non-molar gestational choriocarcinoma: a UK population study
    P Savage and others
    British Journal of Obstetrics and Gynaecology, 2020. Volume 127. Pages 1102-1107

  • M-EA (methotrexate, etoposide, dactinomycin) and EMA-CO (methotrexate, etoposide, dactinomycin / cyclophosphamide, vincristine) regimens as first-line treatment of high-risk gestational trophoblastic neoplasia
    K Singh and others
    Cancer Therapy and Prevention, 2020. Volume 149. Pages 2335-2344

  • Management and Outcomes of Patients with Stage I and III Low-Risk Gestational Trophoblastic Neoplasia Treated in Sheffield, UK, from 1997-2006
    MC Macdonald and others
    Journal of Reproductive Medicine, 2016. Volume 61. Pages 341-346

  • Treatment of low-risk gestational trophoblastic neoplasia
    MC Winter
    Best Practice and Research Clinical Obstetrics and Gynaecology, 2021. Volume 74. Pages 67-80

Last reviewed: 
19 Jun 2023
Next review due: 
19 Jun 2026

Related links